Vascular Stock Analysis

Vascular Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.35. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vascular Biogenics recorded a loss per share of 0.2. The entity had not issued any dividends in recent years. Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. For more information please call Dror Harats at 972 8 993 5000 or visit https://www.vblrx.com.

Vascular Biogenics Investment Alerts

Vascular Biogenics Upcoming and Recent Events

Vascular Biogenics SEC Filings

Vascular Biogenics Thematic Classifications

Vascular Stock Institutional Investors

Note, although Vascular Biogenics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vascular Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 17.78 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vascular Biogenics's market, we take the total number of its shares issued and multiply it by Vascular Biogenics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Vascular Profitablity

Management Efficiency

Vascular Biogenics has return on total asset (ROA) of (0.2912) % which means that it has lost $0.2912 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5952) %, meaning that it created substantial loss on money invested by shareholders. Vascular Biogenics' management efficiency ratios could be used to measure how well Vascular Biogenics manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.83 in 2023. Return on Average Equity is likely to drop to -1.06 in 2023. Total Liabilities is likely to gain to about 8 M in 2023. Current Liabilities is likely to gain to about 6.9 M in 2023

Technical Drivers

As of the 21st of September, Vascular Biogenics has the Coefficient Of Variation of 44185.5, risk adjusted performance of 0.0102, and Semi Deviation of 4.41. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vascular Biogenics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Vascular Biogenics, which can be compared to its competition. Please validate Vascular Biogenics jensen alpha and semi variance to decide if Vascular Biogenics is priced more or less accurately, providing market reflects its prevalent price of 0.22 per share. As Vascular Biogenics appears to be a penny stock we also recommend to double-check its total risk alpha numbers.

Vascular Biogenics Price Movement Analysis

Vascular Biogenics Insider Trading Activities

Vascular Biogenics Technical and Predictive Indicators

Vascular Biogenics Forecast Models

Vascular Biogenics' time-series forecasting models are one of many Vascular Biogenics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vascular Biogenics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vascular Biogenics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vascular shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vascular Biogenics. By using and applying Vascular Stock analysis, traders can create a robust methodology for identifying Vascular entry and exit points for their positions.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vascular Biogenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Vascular Stock please use our How to Invest in Vascular Biogenics guide. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

When running Vascular Biogenics' price analysis, check to measure Vascular Biogenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vascular Biogenics is operating at the current time. Most of Vascular Biogenics' value examination focuses on studying past and present price action to predict the probability of Vascular Biogenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vascular Biogenics' price. Additionally, you may evaluate how the addition of Vascular Biogenics to your portfolios can decrease your overall portfolio volatility.

Is Vascular Biogenics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vascular Biogenics. If investors know Vascular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vascular Biogenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Vascular Biogenics is measured differently than its book value, which is the value of Vascular that is recorded on the company's balance sheet. Investors also form their own opinion of Vascular Biogenics' value that differs from its market value or its book value, called intrinsic value, which is Vascular Biogenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vascular Biogenics' market value can be influenced by many factors that don't directly affect Vascular Biogenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vascular Biogenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vascular Biogenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vascular Biogenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.